Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02457793 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02457793 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 24 participants.
The verdict
NCT02457793, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.
Interventions
- DRUG Cobimetinib
- DRUG GDC-0994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-06-16 |
| Est. Completion | 2016-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02457793
The ClinicalTrials.gov registry entry for NCT02457793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cobimetinib is the first listed.
NCT02457793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02457793 about?
NCT02457793 is a clinical study titled "A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors". This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or ...
What is the current status of trial NCT02457793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-06-16. Estimated completion is 2016-12-05.
What interventions are being tested in trial NCT02457793?
The interventions under investigation include: Cobimetinib (DRUG), GDC-0994 (DRUG).
Who is sponsoring clinical trial NCT02457793?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.